The rapid deepening of the understanding of the molecular mechanisms of angiogenesis has led to the emergence of antiangiogenic drugs to treat cancer, with thousands of patients benefitting from vascular endothelial growth factor (VEGF) and angiopoietin inhibitors [3, 4]. This evidence concerns the gene VEGFA and cancer.